Media Articles Related to Metoprolol and Hydrochlorothiazide (Metoprolol / Hydrochlorothiazide)
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Health News from Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. Breast cancer survivors therefore should watch their weight and get regular exercise so that they can enjoy a high quality of life. These findings, by lead author Nadia Obi of the University Medical Center Hamburg-Eppendorf, who collaborated with the group of Prof.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
How the body regulates neuro-hormone has implications for hypertension, pain, stress, depression
Source: Anxiety / Stress News From Medical News Today [2014.02.12]
New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.
Published Studies Related to Metoprolol and Hydrochlorothiazide (Metoprolol / Hydrochlorothiazide)
Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. [2009.07.22]
OBJECTIVE: High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality. The primary objective was to evaluate the efficacy of metoprolol XL/chlorthalidone against metoprolol XL/hydrochlorothiazide with respect to mean fall in systolic and diastolic blood pressure. The secondary objective was to compare the response rates and to evaluate the tolerability of study medications in patients with mild-to-moderate essential hypertension... CONCLUSION: Chlorthalidone in combination with metoprolol XL is as effective and well tolerated as widely used combination of metoprolol XL/HCTZ, thus providing an alternative therapeutic option.
Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. [2006.12]
BACKGROUND: To attain goal blood pressure (BP), many hypertensive patients require combination antihypertensive therapy. Thiazide diuretic/beta-blocker regimens lower BP, and clinical studies indicate that they reduce the risk for cardiovascular consequences of hypertension. Fixed-dose combination tablets can simplify multidrug treatment regimens... CONCLUSIONS: Extended-release metoprolol/hydrochlorothiazide is an effective antihypertensive combination that offers additive antihypertensive contributions from both components.
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. [2004.11.10]
CONTEXT: Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers. OBJECTIVE: To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors... CONCLUSIONS: Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension. The effects of the 2 beta-blockers on clinical outcomes need to be compared in long-term clinical trials.
Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. [2003.12]
The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, telmisartan, on left ventricular hypertrophy (LVH) compared with the b-blocker, metoprolol, at similar antihypertensive doses.A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population.
[Comparative study between bisoprolol and metoprolol, combined with hydrochlorothiazide, as antihypertensive therapy] [2000.11]
The main objective of this research was to compare the efficacy and security of bisoprolol (B), a new cardioselective beta-blocker, that does not have intrinsic sympathomimetic activity, and metoprolol associated to hydrochlorothiazide (HCTZ), in the treatment of patients with mild to moderate hypertension...
Clinical Trials Related to Metoprolol and Hydrochlorothiazide (Metoprolol / Hydrochlorothiazide)
Factorial Study of Metoprolol Succinate TOPROL-XL (324A) [Completed]
The purpose of this research study is to determine if treatment with the combination of
metoprolol succinate and hydrochlorothiazide is more effective at lowering blood pressure
than treatment with either of the two drugs alone. The study will also determine which
combined doses of metoprolol succinate and hydrochlorothiazide are most effective at lowering
blood pressure (without unacceptable side effects), and whether it is possible to combine
both drugs in a single tablet to simplify blood pressure treatment.
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's metoprolol
tartrate tablets to Novartis' Lopressor® tablets following a single, oral 50 mg (2 x 25 mg
tablets for Mylan's formulation and 1 x 50 mg for Lopressor®) dose administered under fed
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's metoprolol
tartrate tablets to Novartis's Lopressor® tablets following a single, oral 100 mg (1 x 100
mg) dose administered under fed conditions.
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects [Completed]
This was a 52-week, multicenter, open-label study to determine the safety, tolerability and
pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol
CR/XL) in hypertensive pediatric subjects. The study population included school age children
(age 6 to 12 years < Tanner Stage 3) and adolescents (> 12 years old or > Tanner Stage 3 to
16 years old) of both genders. Because response to some therapies in adult hypertension
appears to be different in black and non-black populations, the recruitment will have a
mixture of black and non-black subjects. Pharmacokinetic measurements were performed on a
subset of patients. Thirty subjects (15 subjects each in the 6 to 12 year age group and the
13 to 16 year age group) had a series of blood samples drawn. All subjects had a trough
plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18)
with the exception of those subjects who completed Protocol 307B (16 week open-label
Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan metoprolol
tartrate/hydrochlorothiazide 100/50 mg tablets to Novartis Lopressor HCT® 100/50 mg tablets
following a single, oral 100/50 mg (1 x 100/50 mg) dose administration under fed conditions.